All In Biotech

NDA 020838 · Ani Pharms

Atacand

Candesartan Cilexetil · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jun 4, 1998

Approved uses

5

Original approval plus efficacy supplements

Registered trials

176

52 Phase 3, 9 recruiting

FAERS reports

26,474

23,278 serious, 2,476 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue candesartan cilexetil as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue candesartan cilexetil as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )

What it is approved for

From the label in effect Jan 15, 2026.

Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil is indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other...

Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ATACAND · CANDESARTAN CILEXETIL 16MG · TABLET, ORAL · Prescription · TE AB
  • ATACAND · CANDESARTAN CILEXETIL 4MG · TABLET, ORAL · Prescription · TE AB
  • ATACAND · CANDESARTAN CILEXETIL 32MG · TABLET, ORAL · Prescription · TE AB
  • ATACAND · CANDESARTAN CILEXETIL 8MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Candesartan Cilexetil" as an intervention, any sponsor and status, largest first.

All 176 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,752
  • fatigue1,751
  • nausea1,666
  • headache1,637
  • drug ineffective1,623
  • dizziness1,519
  • diarrhoea1,389
  • malaise1,380
  • off label use1,330
  • fall1,296
  • pain1,249
  • vomiting1,164

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004461
2005543
2006609
2007853
2008909
20091,077
20101,382
20112,050
20122,398
20131,086
2014988
2015977
2016843
2017815
20181,332
20191,424
20201,455
20211,261
20221,313
20231,225
20241,243
20251,195
20261,034

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atacand (Candesartan Cilexetil)

2024 spending

$1.8M

Beneficiaries

649

2,894 claims

Per beneficiary

$2,718

$8.66 per unit

View as table
YearSpending
2020$3,108,482
2021$2,636,639
2022$2,230,939
2023$2,033,228
2024$1,764,048

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 184 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.